0001104659-23-033858.txt : 20230317
0001104659-23-033858.hdr.sgml : 20230317
20230317161124
ACCESSION NUMBER: 0001104659-23-033858
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230316
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Branning Todd P.
CENTRAL INDEX KEY: 0001765274
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35963
FILM NUMBER: 23742671
MAIL ADDRESS:
STREET 1: C/O AMNEAL PHARMACEUTICLAS, INC.
STREET 2: 400 CROSSING BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001173281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465622433
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
BUSINESS PHONE: 412-763-3350
MAIL ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
FORMER COMPANY:
FORMER CONFORMED NAME: Ohr Pharmaceutical Inc
DATE OF NAME CHANGE: 20090819
FORMER COMPANY:
FORMER CONFORMED NAME: BBM HOLDINGS, INC.
DATE OF NAME CHANGE: 20070402
FORMER COMPANY:
FORMER CONFORMED NAME: PRIME RESOURCE INC
DATE OF NAME CHANGE: 20020513
4
1
tm239873d2_4.xml
OWNERSHIP DOCUMENT
X0306
4
2023-03-16
0
0001173281
NeuBase Therapeutics, Inc.
NBSE
0001765274
Branning Todd P.
C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR
PITTSBURGH
PA
15219
0
1
0
0
Chief Financial Officer
Common stock
2023-03-16
4
A
0
54200
0
A
84200
D
Restricted stock units to be settled by the issuance of one share of common stock for each restricted stock unit that is earned; 25% of which shall vest on March 16, 2024 and the remainder of which shall vest monthly thereafter until March 16, 2027, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Restricted stock units are subject to accelerated vesting, subject to certain conditions, in the event of a change of control of the Issuer.
/s/ Todd P. Branning
2023-03-17